SPTAN1
Overview
SPTAN1 (Spectrin Alpha, Non-Erythrocytic 1) encodes alpha-II-spectrin, a cytoskeletal scaffolding protein. It was identified as a newly recognized significantly mutated gene (SMG) in muscle-invasive bladder cancer (MIBC) in the TCGA 2017 comprehensive cohort study. SPTAN1 mutations occur in approximately 12% of MIBC tumors, though its functional role as a driver versus passenger mutation in bladder cancer requires further characterization.
Alterations observed in the corpus
- 12% mutated newly recognized SMG in MIBC (TCGA n=412 cohort) PMID:28988769.
Cancer types (linked)
- BLCA (Bladder Urothelial Carcinoma) — Recurrently mutated in 12% of MIBC; identified as a new SMG in the TCGA 2017 comprehensive cohort PMID:28988769.
Co-occurrence and mutual exclusivity
- Listed alongside other newly identified SMGs such as KMT2C (18%), FAT1 (12%), and CREBBP (12%) in MIBC PMID:28988769.
Therapeutic relevance
- No direct therapeutic association reported; cytoskeletal role may contribute to invasion and metastasis biology PMID:28988769.
Open questions
- Driver versus passenger status of SPTAN1 mutations in MIBC is unresolved; functional studies needed PMID:28988769.
Sources
This page was processed by crosslinker on 2026-05-15.